ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Nashville, TN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Squamous Cell Carcinoma
Lung Cancer

Melanoma trials near Nashville, TN, USA:

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma...

Enrolling
Uveal Melanoma
Drug: Darovasertib

Phase 2

Ideaya Biosciences

Nashville, Tennessee, United States and 24 other locations

safety, tolerability, and preliminary efficacy of belzupacap sarotalocan for the treatment of primary indeterminate lesions and small choroidal melanoma...

Active, not recruiting
Ocular Melanoma
Choroidal Melanoma
Device: Suprachoroidal Microinjector
Device: PDT Laser

Phase 2

Aura Biosciences
Aura Biosciences

Nashville, Tennessee, United States and 21 other locations

binimetinib, and pembrolizumab) given together for the treatment of melanoma that:* is advanced or metastatic (spread to other parts of the ...

Active, not recruiting
Melanoma
Drug: Binimetinib
Drug: Encorafenib

Phase 3

Pfizer
Pfizer

Nashville, Tennessee, United States and 227 other locations

Locations recently updated

and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + tram...

Enrolling
Advanced or Metastatic NRAS-mutant Melanoma
Drug: Trametinib
Drug: Naporafenib

Phase 3

Erasca

Nashville, Tennessee, United States and 4 other locations

efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma...

Enrolling
Ocular Melanoma
Choroidal Melanoma
Device: Suprachoroidal Microinjector
Drug: Sham Treatment

Phase 3

Aura Biosciences
Aura Biosciences

Nashville, Tennessee, United States and 37 other locations

of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma ...

Active, not recruiting
Melanoma
Biological: Durvalumab
Drug: Ceralasertib

Phase 2

AstraZeneca
AstraZeneca

Nashville, Tennessee, United States and 65 other locations

antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotin...

Enrolling
Metastatic Uveal Melanoma
Drug: IDE196
Drug: Nivolumab

Phase 2, Phase 3

Ideaya Biosciences

Nashville, Tennessee, United States and 65 other locations

A Phase 2 study to investigate the efficacy and safety of lerapolturev alone or in combination with a programmed death receptor-1 (anti-PD-1) inhibit...

Active, not recruiting
Melanoma
Biological: Lerapolturev
Biological: Anti-PD-1 Checkpoint Inhibitor

Phase 2

Istari Oncology

Nashville, Tennessee, United States and 11 other locations

to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma...

Active, not recruiting
Melanoma
Biological: Nivolumab
Biological: Nivolumab + Relatlimab Fixed Dose Combination

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Nashville, Tennessee, United States and 171 other locations

Part 1 is the dose escalation of APG-115 in combination with label dose of pembrolizumab.Part 2 is phase II design of APG-115 at recommended phase 2...

Enrolling
Mucosal Melanoma
Melanoma
Drug: APG-115+Pembrolizumab

Phase 1, Phase 2

Ascentage Pharma Group
Ascentage Pharma Group

Nashville, Tennessee, United States and 19 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems